American Society of Hematology

Figure 3.

Intravenous administration of huMkMPs increases in vivo platelet concentrations in WT mice 72 hours after administration. huMkMPs, 2 × 106 (A) or 6 × 106 (B), were administered intravenously into WT BALB/c mice via the tail vein. Murine platelet levels of control mice (untreated) or mice treated with MkMPs were measured 72 hours after huMkMP injection. (C) huMkMPs (6 × 106; n = 8), CHO-MVs (6 × 106; n = 2), or saline control (n = 10) were administered intravenously to WT mice via the tail vein, and murine platelet numbers were measured as percentage of the control at 24 hours. Error bars represent the SEM. **P < .01; ***P < .001.

Intravenous administration of huMkMPs increases in vivo platelet concentrations in WT mice 72 hours after administration. huMkMPs, 2 × 10⁶ (A) or 6 × 10⁶ (B), were administered intravenously into WT BALB/c mice via the tail vein. Murine platelet levels of control mice (untreated) or mice treated with MkMPs were measured 72 hours after huMkMP injection. (C) huMkMPs (6 × 10⁶; n = 8), CHO-MVs (6 × 10⁶; n = 2), or saline control (n = 10) were administered intravenously to WT mice via the tail vein, and murine platelet numbers were measured as percentage of the control at 24 hours. Error bars represent the SEM. **P < .01; ***P < .001.

This Feature Is Available To Subscribers Only